List of Xermelo drug patents

Xermelo is owned by Tersera.

Xermelo contains Telotristat Etiprate.

Xermelo has a total of 5 drug patents out of which 0 drug patents have expired.

Xermelo was authorised for market use on 28 February, 2017.

Xermelo is available in tablet;oral dosage forms.

Xermelo can be used as the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (ssa) therapy in adults inadequately controlled by ssa therapy.

Drug patent challenges can be filed against Xermelo from February, 2021.

The generics of Xermelo are possible to be released after 28 February, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7553840 TERSERA 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
Dec, 2027

(4 years from now)

US8193204 TERSERA Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1- (4-chloro-2-(3-methyl-1H-pyrazol-1-YL)phenyl)2,2,2-trifluoroethoxy)-pyrimidin-4-YL)phenyl)propanoate and methods of their use
Feb, 2031

(8 years from now)

US7709493 TERSERA 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
Feb, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7968559 TERSERA Methods of using 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds
Dec, 2027

(4 years from now)

US8653094 TERSERA Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use
Dec, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 28, 2022
Orphan Drug Exclusivity (ODE) Feb 28, 2024

Drugs and Companies using TELOTRISTAT ETIPRATE ingredient

NCE-1 date: February, 2021

Market Authorisation Date: 28 February, 2017

Treatment: The treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (ssa) therapy in adults inadequately controlled by ssa therapy

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic